Biotechnology company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Wednesday that its novel antibody-drug conjugate (ADC), IPH4502, will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place from 25-30 April 2025 in Chicago.

IPH4502, a Nectin-4 targeting ADC conjugated to exatecan, is currently in a Phase 1 clinical trial for advanced solid tumors. Preclinical data indicate efficacy in tumors with primary and acquired resistance to enfortumab vedotin, as well as those with low to moderate Nectin-4 expression, expanding its potential beyond urothelial carcinoma.

CEO Jonathan Dickinson will also present at the AACR Oncology Industry Partnering Event on 24 April, providing an update on Innate's pipeline and strategic direction.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma develops immunotherapies targeting the innate immune system. Its portfolio includes multi-specific NK cell engagers, ADCs and monoclonal antibodies, with key partnerships with AstraZeneca and Sanofi.